patents articles ↓

An interesting looking patent that was filed in 2006 has come up as reaching filed status. This patent covers the relationship between an oligosaccharide specific to an inflammatory disease, more specifically ocular rosacea. The discovery may lead to both a definitive diagnostic test and new treatments for ocular rosacea. One of inventors of this patent is well known to rosacea sufferers. Dr. Mark Mannis …

A couple of recently awarded patents look both interesting and slightly scary for potential rosacea treatments. These patents cover some kind of device that is stuck to the skin. A small electric charge is used to help an active chemical cross the skin barrier. Some kind of carrier (an electrolyte) allows Zinc ions to flow between the electrodes, across the skin, creating a small charge. …

Galderma, the makers of Oracea are suing Mylan Pharmaceuticals for allegedly infringing 4 patents related to their sub-antimicrobiotic dose doxycycline product Oracea. State University of New York, Galderma Sue Mylan March 20 (Bloomberg) — The State University of New York, Galderma Laboratories LP and New York University sued generic- drug maker Mylan Pharmaceuticals Inc. for allegedly …

A new sansrosa patent application has appeared, and from it was can see clearly what formula will be used for the sansrosa gel and sansrosa cream formulations. We don’t know the official name for the product yet, but it seems to make sense to me to call the product Sansrosa Gel and Sansrosa Cream.

Those following the development of sansrosa closely will be encouraged by this …

My regular patent trolling has unearthed something potentially interesting. The anti-nausea drug Tropisetron is patented by Galderma as a treatment for inflammatory skin conditions including rosacea. Tropisetron is officially known as a 5-HT3 receptor antagonist or a serotonin antagonist. Serotonin (5-HT) is found widely distributed throughout the gut and the central nervous system ADMINISTRATION OF TROPISETRON FOR TREATING INFLAMMATORY SKIN …